We aim to foster a culture of entrepreneurship, innovation and success among engineers in the UK, creating economic growth and societal impact. At the heart of how we do this are the Hub Members, the promising entrepreneurs who we support through our programmes, and our Hub Mentors, the business leaders who volunteer their expertise and time to help the Hub Members succeed.
From manufacturing to medtech, our Hub Membership is made up of some of the UK’s most innovative entrepreneurs. But don’t just take our word for it: read more about our Hub Members to see how they are, without exaggeration, changing the world.
Losing your eyesight is one of the most devastating things that can happen to a person.
Some forms of vision loss that affect the retina, such as age-related macular degeneration (AMD), or diabetes can be treated. This requires monthly injections into the eye for at least five years. The treatment works well for most people but requires regular outpatient visits and there is a small risk of additional complications from the injection process itself.
There is a real need to make treatments better, safer and more convenient.
I-Daruma has developed a technology that takes the same treatment and makes it possible to deliver the currently injected drugs as eye drops instead. It works by creating short-lived nanoparticles that are mixed with the drugs. These then dissociate at the target tissues, releasing the drug. The nanoparticles are made from compounds that naturally occur in the body and are well-tolerated, giving the technology the advantages of nanoparticle delivery without the toxicity associated with current nanoparticles.
The eye drops will address several issues with the current treatment regime. While injections must be administered by trained healthcare professionals in a clinical setting, eye drops can be administered by the patient themselves anywhere, resulting in large healthcare cost savings.
Worldwide, there were 14 million intravitreal injections performed in 2018 and it’s a number that has been growing 20% year-on-year. The drivers of treatment are the ageing global population and metabolic disease such as diabetes. About one third of people living with diabetes will suffer from diabetic retinopathy. Age-related macular degeneration (AMD) is also a leading cause of vision loss in Europe and the US. Currently, 196 million people are estimated to be affected by AMD globally, a figure expected to hit 288 million by 2040.
In the next 12 to 18 months, Naa Dei anticipates applying for InnovateUK Grant funding and looks forward to completing pre-clinical trials and having a dossier for approval for clinical trials.
2020 – Awarded a Royal Academy of Engineering’s Enterprise Fellowship.
2020 – Piloting trials of technology with a pharmaceutical company.
“[The Enterprise Fellowship] has opened my eyes to what goes into turning a neat idea into a business and has equipped me with tools to do so. It’s an amazing network of people at different stages of their enterprises, and I’ve found it very supportive.”
Sustainable construction demands better management of social and environmental impact. To achieve this, reliable, efficient tools are needed to make sense of large volumes of data across the range of related fields.
Qflow is a cloud-based platform that enables construction projects to manage their environmental risk and stay compliant with environmental standards.
Qflow brings together machine learning and the Internet of things to capture and analyse environmental data, making it easier to identify and manage risk. This increases productivity and reduces cost while positively impacting the built environment.
The technology connects to existing, on-site systems to automate real-time data collection and analysis. This leads to better informed decisions, more accurate predictions and the ability to generate standardised reports. It reduces costs associated with delays and mitigation processes caused by unmanaged environmental risk.
Trials have shown that Qualis Flows’ solutions can improve data capture against existing competitors by over 100%. Four pilot programmes are scheduled for spring 2019 to further validate the technology’s use in monitoring aspects such as waste, noise, air quality and vibration.
Brittany Harris brings significant experience in civil engineering as she leads a multi-skilled team of engineers, environmental professionals and software architects as Qualis Flow brings its solutions to market.
The array of switches, buttons, wheels and controls that help us to interact with electronics all rely on bulky and complex networks of sensors that can cost a lot to create.
TG0 has developed a new technology for making interactive 3D controls that are ergonomic, intuitive and engaging. Its solutions replace complicated networks of electronic sensors with one uniform, flexible, touch-sensitive material.
Driven by artificial intelligence algorithms and advanced signal processing, TG0’s platform technology can accurately detect variations in touch across a single flexible surface. This allows its material to easily sense pressure, location, speed, direction and movement allowing users to engage in more intuitive ways.
As Co-Founder, Ming leads research and development for the technology’s hardware. TG0’s seamless, interactive surfaces can be used in a range of applications including tactile gaming controls, car dashboard controls and ergonomic computer peripherals such as keyboards, amongst many others.
TG0 is also exploring how its technology can be used to make interactive products that are more accessible for the visually impaired.
Since its launch in 2016, TG0 has worked with high profile brands and manufacturers in the consumer and automotive sector and built a patent portfolio with more than ten international patent entries to date. A rapidly growing team is helping the company to expand and target a range of industries including sensor-embedded industrial robots, wearables, gadgets and underwater electronics.
"Getting to grips with a whole new mechanism for sensing and control doesn’t come naturally when you’ve spent your life learning to use another system."
The flexible and printed electronics markets are working towards having speedy, defect-free manufacturing processes. To achieve this, they need new inspection systems that allow live testing and enable real-time quality assurance without stopping production.
Dr Muhamedsalih has helped create a multi-wavelength polarising interferometer (MPI) for in-line surface metrology. It operates at the micro/nano-scale level and can be used for real time inspections of moving surfaces. The interferometer is combined with a software method to handle larger amount of data for surface analysis without direct interaction from the operator.
The system detects and characterises defects. This means that manufacturers will be able to understand what causes faults and take measures to correct them. Importantly, the technology is sufficiently robust to be used on the shop floor.
Hussam is now working to validate the MPI’s performance with world-leading manufacturers and research centres. His innovation is being tested by the UK Catapult National Centre for Printable Electronics – Centre for Process Innovation. His proof of concept system should reach Technology Readiness Level 9 before the end of 2021 and be ready to launch and available to buy soon after.
Analysts have forecast that the global metrology market will grow to over $600 million by 2023 in the traditional manufacturing market. Hussam’s technology also fits into the printed and flexible electronics markets, which are predicted to grow to $77 billion by 2023.
For Dr Muhamedsalih, the Enterprise Fellowship experience has: “allowed me to structure my business model and test it out by intensive direct interaction with industry and potential clients.”
Women deserve a better way of getting professionally fitted for bras. The lack of care and proper training within the bra industry means that bra-sizing confusion is a never-ending debate. Inefficient practices result in 80% of women wearing bras that don’t fit properly and billions of pounds lost every year in size- and fit-related exchanges and returns.
Combining state-of-the-art computer vision with data from real-life women (our co-creators), Brarista is bringing professional bra-fitting to bra-wearers’ homes. Its technology makes it possible for clients to find their best fit across product lines simply by using their phone camera.
Researching this technology to ensure its usefulness and accuracy is technically complex. Brarista is working hard to continue building, testing, and improving the current prototype before conducting technical trials.
The ongoing pandemic gave Brarista an opportunity to collaborate with Boost Innovations Ltd to apply its technology to fit breast prostheses online for breast cancer survivors (classified by the NHS as a higher-risk group). Research shows that getting bra-fitted using a tape-measure results in a 70% inaccuracy rate, but this is still the most popular method used by high street bra-fitters and online bra-fitting guides. Brarista hopes that its technology will improve the accuracy by at least 40% to be on par with professional bra-fitting by eyesight.
2018 - Won the Most Innovative Idea at the UCL Innovation and Enterprise Launch Programme
2019 - Team formation and acquired trial interests from the industry
2019 - Selected as a startup to be mentored by DeFine Network EU (a European Commission-funded FashionTech Community).
2019 - Selected as one of seven startups to join Women in AI & Data in Israel with InnovateUK
2019 - Highly Commended Award at the Academy’s Enterprise Hub Launchpad Competition Final
2020 - Crowdfunded successfully and matchfunded with NatWest Back Her Business
2020 - Acquired a new research client to apply its technology to fit breast prosthesis online
To find out more abut Brarista visit https://www.brarista.co/
“[The programme has helped by] providing the network of supporters, coaches and mentors that help me grow as an entrepreneur.”
For decades, satellites have been getting smaller but the rockets that launch them haven’t. Most active vehicles are still designed for historically large satellites and this is forcing a new generation of SmallSats to rideshare on enormous rockets in an expensive system of compromise.
Of the small satellites forecast to be launched between 2021 and 2030, 70% are predicted to fall in the under 250-kilogram weight class. However, launch vehicles that can operate at this weight lack appropriate propulsion systems. There is a clear market demand for dedicated launch vehicles that can take small satellites exactly where and when they need to go, but the fundamental technical challenge is that rocket engines and their associated pumps and turbomachinery are incredibly difficult to scale down. Attempts to scale down existing technology commonly result in spiralling costs and complexities.
Protolaunch believes that the right engine is the key to unlocking a successful microlauncher, and aims to supply that propulsion. It is developing an engine based around a novel thermodynamic cycle designed specifically for small payloads from the outset. This is possible because of its core engine technology, which acts as the enabler for a new type of launch vehicle.
The Protolaunch engine has three key advantages:
“Over the next 12 to 18 months, we look forward to working with the Royal Academy of Engineering as we build our long-term commercial strategy and start to engage with larger aerospace partners and customers.”
Better intraoperative guidance can help reduce patient morbidity and healthcare costs across surgical specialties. For example, brain tumour patients undergoing surgery have significantly improved outcomes and increased life expectancy if complete tumour removal is achieved. However, maximal resection needs to be balanced with the goal of healthy tissue preservation in order to minimise patient risk and neurological impairment. Yet, even with the most advanced current techniques, intraoperative decisions with potentially life-changing consequences are still based on the surgeon’s subjective visual assessment.
Hypervision Surgical has designed an AI-powered imaging system for wide-field tissue characterisation that attaches to and enhances existing surgical equipment. For the first time, surgeons will have real-time actionable information on tumour and critical brain structure margins during surgery. In addition, their system can monitor vital physiological tissue properties thereby increasing surgical precision and patient safety while optimising resection.
As a King’s College London spin-out, Hypervision Surgical is embedded in the St Thomas’ MedTech Hub and has close ties with King’s Health Partner hospitals. Further clinical studies are scheduled to develop and evaluate their technology to achieve commercial readiness.
Dr Ebner was awarded an Enterprise Fellowship award in 2020 to support him as he leads Hypervision Surgical in bringing its innovations to market.
Modern surgical implants use ‘press-fit’ and are hammered into place by the surgeon, creating friction that holds the implant in place. If the surgeon impacts the implant too rigorously, the bone may be over-stressed and fracture.
Bone fracture during hip replacement surgery affects between 2% and 8% of patients. If fracture occurs the patient is seven times more likely to need expensive revision surgery and twice as likely to die from complications.
Additive Instruments’ technology is a ‘smart’ surgical tool that can sense the force being applied to the instrument and adjust it to reduce the chances of fracture. By reducing the variation in impaction force, the technology also reduces the learning curve for new surgeons – reducing the likelihood of fracture through inexperience.
In the UK and US, 400,000 hip replacement procedures are conducted every year. If a conservative estimate of 2% of these surgeries were to result in fracture, 8,000 patients would suffer a painful and debilitating injury each year, most requiring revision surgery at great expense. These surgeries are estimated to cost £25 million every year.
Additive Instruments’ technology has been proven in the laboratory, so its next key milestone is to validate the product in a clinical environment, first with specimens and subsequently with live patients. Once the efficacy of the product has been proven, Additive Instruments will apply for a CE mark – a key achievement for any medical device.
Early laboratory development was supported by the Wellcome trust with a product translation award. Following the support of the Royal Academy of Engineering’s Enterprise Hub, Additive Instruments has been awarded an i4i (invention for innovation) award from the National Institute for Health Research (NIHR). This funding will help it achieve its goal of first clinical usage within the next two years.
“The real value of the Enterprise Fellowship is in the soft support I have received. Business coaching, workshops to develop interpersonal and planning skills, as well as brilliant insights from my mentor have all been hugely useful as Additive Instruments starts its journey into the commercial world.”
Commercial drones are now being used for several different roles such as mapping farms, inspecting buildings and search-and-rescue operations. Most commercial drone automation software on the market is generic, meaning drone operators and enterprises requiring customised solutions are forced to use many different types of software to get their job done. This becomes incredibly expensive and unreliable.
Hammer Flights Ltd is the world’s first adaptive flight automation software for unmanned aerial vehicles. It is highly versatile, supporting many different types of flight automation and yet is extremely simple to use. Using modular software architecture and APIs , the software morphs according to the task at hand.
Hammer aims to empower every drone operation in the world with adaptive flight automation to make their operations more productive, creative and safe. Its next key milestone is to understand how it can scale its enterprise offerings over the next 12 to 18 months.
The commercial drone industry is currently worth $13 billion and is expected to grow to $45 billion by 2025. A lot of this growth is attributed to enterprises rapidly setting up in-house drone teams and integrating drones into their existing workflows. Each one of these businesses will be looking for a customised flight automation solution that adapts to the needs of their business.
Hammer is currently grant funded by Ordnance Survey – the UK’s largest mapping agency – and the Royal Academy of Engineering through its Enterprise Fellowship programme. It has also formed strategic partnerships within the drone ecosystem.
“The Enterprise Fellowship has provided us with an amazing network of fellow entrepreneurs and mentors that we can learn from throughout our journey.”
What makes us different is the Academy’s Fellows and our wider Mentor network – an unrivalled community of the UK’s most successful industry leaders, technology experts and entrepreneurs. Find out more about our Mentors and their areas of expertise.
John is Professor of Optoelectronic Systems and Dean of transnational Education at the University of Glasgow.
He moved to Glasgow in 1986, where he established an internationally leading research group addressing linear and nonlinear integrated optoelectronic systems. He developed new integration technologies for photonic integrated circuits based on quantum well devices and quantum well intermixing, which ultimately led to the formation of the spin-out company Intense Ltd in 2000.
Intense developed the world’s most advanced integrated laser systems, bringing monolithic laser arrays together with electronic ASICs and optics for precise energy delivery in a range of applications from printing to material processing. The monolithic laser arrays pushed reliability and manufacturing yields to new levels.
John has extensive experience of operating in both academic and high-technology industrial environments, and as a result has an excellent understanding of spinning out IP and creating commercial value from an academic base.
He has been involved with several start-up companies including Kelvin Nanotechnology Ltd (1997-2000); Compound Semiconductor Technologies Ltd (1999-2000) and Intense Ltd (now Intense Inc) (2000-2009).
John was elected a Fellow of the Royal Academy of Engineering (FREng) in 2007; Fellow of the Royal Society of Edinburgh (FRSE) in 2000; Fellow of IEEE (FIEEE) in 2000 ‘for contributions to development of integrated optics based on semiconductor quantum well devices’; and Fellow of the Optical Society (FOSA) in 2016 for ‘for contributions to quantum and photonics technologies and systems in III-V compound semiconductors’.
Mark has extensive experience in growing and supporting businesses across a wide range of sectors covering oil and gas, energy, defence, instrumentation and communications. Currently he heads Mercia Fund Management’s Electronics, Hardware and Telecoms division.
He holds various positions on several boards, including Chairman of Oxifree Global Ltd; Non-Executive Director of Rawwater Engineering Company Ltd and Non-Executive Director of Smart Reamer Drilling Systems Ltd. He is also on the Advisory Board for Synaptec Ltd and Spectrum Corporate Finance LLP.
Mark holds an engineering degree from Cambridge University, a PhD from Southampton University and an MBA from Edinburgh University. He is a fellow of the Institute of Engineering and Technology.
John is the Director of the Cambridge Engineering Design Centre following a seven-year spell with PA Consulting Group's Technology Division where he was Manager of the Advanced Process Group. He was appointed director of the Engineering Design Centre in 1997 and a University Professor in 2004.
At PA John gained wide experience of product development with a particular focus on the design of medical equipment and high-integrity systems, where clients required a risk-based systems approach to design to ensure timely delivery of safe systems. John is directly involved in the teaching of design at all levels of the undergraduate course.
His research interests are in the general area of engineering design, particularly the development of design methodologies to address specific design issues, for example, process management, change management, healthcare design and inclusive design. As well as publishing over 800 papers, he has written and edited a number of books on medical equipment design, inclusive design and process management.
John is currently leading a team with the Royal Academy of Engineering, the Royal College of Physicians and the Academy of Medical Sciences to develop a systems approach to healthcare redesign and continuous improvement. He was made Fellow of the Royal Academy of Engineering in 2012.
Bill is a leading scientist worldwide in the field of Medical Materials. His major research contributions have been recognised by numerous international awards, medals and memberships.
He has been the Professor of Medical Materials at the University of Cambridge; served as Director of Cambridge Pfizer Institute for Pharmaceutical Materials Science; Cambridge Director of CMI Interdisciplinary Research Cluster in Biomaterials and Tissue Engineering and Director of University of London Interdisciplinary Research Centre (IRC) in Biomedical Materials. He has been Head of Department, Dean, and Governor at Queen Mary University of London.
He has been the editor of the Journal of The Royal Society: Interface, the Journal of Materials Science: Materials in Medicine, the Journal of Materials Science, and of the Journal of Materials Science Letters.
Bill is Emeritus Professor of Medical Materials in the University of Cambridge. He is internationally recognised for his pioneering research contributions to biomaterials for medical devices, with awards including the Royal Academy of Engineering Prince Philip Gold Medal; the Royal Society Armourers and Brasiers Company Medal; the Kelvin Medal; the European Society for Biomaterials George Winter Award; the Japanese Society for Biomaterials Medal; the Institute of Materials Griffiths Medal and Chapman Medal; the UK Society for Biomaterials President's Prize; the Acta Metallurgica H.H. Holloman Award and the International Union for Physical Sciences and Engineering in Medicine Award of Merit.
Professor Bonfield's exceptional interdisciplinary contribution has been recognised by his election to all three UK National Academies as a Fellow of the Royal Society (FRS), a Fellow of the Royal Academy of Engineering (FREng) and a Fellow of the Academy of Medical Sciences (FMedSci).
Professor Joe McGeehan completed his PhD in 1971 and since then has been instrumental in many aspects of research and teaching in the field of Communications. He is even referred to as the 'godfather of mobile communications'.
Joe has been conducting research and development into mobile communications technologies and systems since 1973. Working with colleagues, he has pioneered many of the major developments in the field including: deterministric ray-tracing for propagation prediction and network coverage; linear modulation techniques and systems; linearised RF power amplifiers; SMART antennas; wideband CDMA for 3G; WLAN technologies and 60GHz propagation and communication systems.
Professor McGeehan's achievements in research have been acknowledged by membership of a number of national and international committees in the field of Communications, external examiner positions and mentoring of start-up companies.
His involvement in Communications over several decades led to being awarded in the Queens Birthday Honours 2004 a CBE for ‘services to the Communications Industry’. Joe was elected a Fellow of the Royal Academy of Engineering in 1994 and was listed in 2004 as No.6 in the world’s ‘Technology AgendaSetters’ by silicon.com (USA) (N.B., Bill Gates was placed No.2).
Billy's vision is to change the way we currently diagnose and monitor serious disease. He is the co-founder of Owlstone, which aims to become the global leader in the non-invasive detection of cancer, infectious disease and inflammatory disease.
It is best to detect disease as early as possible: treatments are more effective, less involved and more lives can be saved. There is no better example of this than with cancer. If detected early, the chances of cancer survival can be as good at 95%. But this drops massively to about 5% at later stages. Unfortunately there are still far too many people detected at later stage.
To address this, Owlstone Medical has developed a breathalyzer for disease. Every time you breathe out there are hundreds of chemicals on your breath. Some are telltale markers of disease, which Owlstone microchip chemical sensor technology is able to detect. Through early detection Owlstone have set a goal to have saved 100,000 lives and $1.5 billion in health care costs by 2020.
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners and is heavily involved in the creation and realisation of new technologies and IP. He is also active in business development, demonstrating how the Owlstone technology can be a paradigm shift in detection applications and deployment scenarios.
Prior to his time at Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Cliff is a physicist with interests in soft matter, liquid crystals, displays, optoelectronics and photonics. Acknowledged as an inspirational technical leader and strategist, inventor and innovator, entrepreneur and public speaker, he is an experienced and award winning Chief Technology Officer, company founder and director. Cliff is currently a Professor of Physics; EPSRC Fellow of Advanced Manufacturing at the University of Leeds.
He is experienced in raising venture capital, growing ZBD Solutions Limited from nothing to over $30M sales per annum, becoming Europe's second fastest growing technology company for 2012.
Professor Jones is a Fellow of the Royal Academy of Engineering, Chartered Physicist and Fellow of the Institute of Physics, Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce, and Senior Member of the Society for Information Display.
Andrew has over 30 years’ design and operational experience in the biopharmaceutical industry, with direct responsibility for manufacturing, logistics, maintenance and capital programme management.
He has developed Biopharm Services into a leading provider of bioprocess modelling and knowledge management tools that support bioprocess innovation.
Prior to Biopharm Services, Andrew was Director of Engineering and Logistics at Lonza Biologics and holds an MSc in Biochemical Engineering from UCL. He was a finalist in “The Manufacturing Processing Thought Leader of the Decade” category at the 2012 BioProcess International Awards and is a Fellow of the Royal Academy of Engineering (2013).
Malcolm has been an active supporter of the Academy’s entrepreneurship activities in the UK and abroad for many years.
Following a distinguished career at Shell, Malcolm is currently Chair of Engineering UK, President of the Energy Institute and also finds time to Chair the Judging Panel of the Academy’s Africa Prize for Engineering Innovation.
Malcolm was elected a Fellow of the Royal Academy of Engineering in 2002.